Abstract
45 patients on maintenance ganciclovir for treated cytomegalovirus (CMV) retinitis were reviewed retrospectively. Treatment was given at 30 mg/kg/week in 3 divided doses: Monday, Wednesday, Friday. The median time to clinical relapse was 5.4 months. This is similar to that reported with higher frequency maintenance regimens. The high degree of immunodeficiency (median CD4 count 16 cells/microliters) and poor prognosis (median survival 8.2 months) associated with CMV retinitis were confirmed.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications*
-
Adult
-
Aged
-
Cytomegalovirus Infections / complications
-
Cytomegalovirus Infections / drug therapy*
-
Eye Infections, Viral / complications
-
Eye Infections, Viral / drug therapy*
-
Ganciclovir / administration & dosage
-
Ganciclovir / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Opportunistic Infections / complications
-
Opportunistic Infections / drug therapy
-
Prognosis
-
Recurrence
-
Retinitis / complications
-
Retinitis / drug therapy*
-
Retrospective Studies